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A B S T R A C T
Klotho, named after the ancient Greek goddess Klotho, the spinner (of life), is an ag-
ing suppressor or longevity-related gene, discovered in 1997. A defect in the Klotho 
gene expression in mice leads to phenotypes resembling human premature or acceler-
ated aging syndromes, with a short lifespan, infertility, arteriosclerosis, skin atrophy, 
osteoporosis and emphysema, while Klotho overexpression is associated with extend-
ed longevity. The Klotho gene encodes a transmembrane protein expressed mainly 
in the kidney, the parathyroid gland and the choroid plexus. The Klotho protein has 
multiple regulating functions, can serve as a useful biomarker and may have potential 
therapeutic applications, and thus an emerging role in reno-cardio-vascular disease, 
which is briefly explored in this overview. 
According to ancient Greek mythology, Klotho or Clotho (in Greek: Κλωθώ), 
the Spinner, is the youngest of the 3 Fates or Moires: Klotho who spins, Lachesis who 
measures, and Atropos who cuts the thread of life. Klotho was in charge of spinning 
the thread of human life. She also made critical decisions, as to when a person was to 
be born, saved or die, thus in essence controlling people’s lives. Klotho is also the name 
given to an aging suppressor or longevity-related gene, discovered in 1997.1-3 A defect in 
the Klotho gene expression in mice leads to phenotypes resembling human premature 
or accelerated aging syndromes, with a short lifespan, infertility, arteriosclerosis, skin 
atrophy, osteoporosis and emphysema, while Klotho overexpression is associated with 
extended longevity. Klotho knock-out mice develop osteopenia and vascular or other 
ectopic calcifications, similar to those seen in chronic kidney disease (CKD). They also 
have shorter lifespan and senescent changes in many other organs and tissues, includ-
ing the heart, lungs, muscles, skin, thymus, gonads, hearing, and motor neurons. The 
Klotho gene encodes a (130-kDa) single-pass transmembrane protein expressed mainly 
in the kidney, the parathyroid gland and the choroid plexus,4 and to a lesser extent in 
placenta, prostate and small intestine. The Klotho protein has multiple (pleiotropic) 
regulating functions with an emerging role in cardiorenal disease.5
There are two separate forms of Klotho protein, membrane (beta) Klotho and 
secreted (alpha) Klotho.2,3 Membrane Klotho forms a complex with fibroblast growth 
factor (FGF) receptors and functions as an obligate co-receptor for FGF-23, a bone-
derived hormone (the major phosphatonin) that induces phosphate excretion into 
urine. Mice lacking Klotho or FGF-23 not only develop phosphate retention but are 
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also afflicted by a premature-aging syndrome, pointing to 
a link between phosphate metabolism and aging. Secreted 
α-Klotho functions as a humoral factor that regulates activ-
ity of multiple glycoproteins on the cell surface, including 
ion channels and growth factor receptors such as insulin/
insulin-like growth factor-1 receptors, and inhibits acute 
kidney injury, vascular calcification, renal fibrosis, and cancer 
metastasis in an FGF-23-independent manner. The activity 
of this extracellular domain of Klotho increases the expres-
sion of antioxidant enzymes and provides cell and organism 
resistance to oxidative stress.
Klotho is expressed in areas involved with calcium regula-
tion, predominantly in the kidney distal convoluted tubules, but 
also in the brain choroid plexus (which produces cerebrospinal 
fluid) and the parathyroid gland. Klotho acts as a cofactor for 
interaction of FGF23 with FGF R1. This interaction negatively 
regulates 1αhydroxylase, the rate limiting enzyme in the syn-
thesis of 1,25(OH)2D3 (vitamin D). Klotho deficient mice 
show severe hyperphosphatemia and ectopic calcification of 
soft tissues due to excess vitamin D. Although the klotho gene 
was first reported as having anti-ageing properties in mice, 
human Klotho gene polymorphisms have been linked with 
reduced longevity.
Chronic kidney disease (CKD) has been suggested as a 
state of Klotho deficiency in the kidney, plasma, and urine.6,7 
Secreted Klotho protein has FGF-23- independent phospha-
turic and calcium-conserving effects via its paracrine action 
on the proximal and distal tubules, respectively.8 On the other 
hand, Klotho deficiency causes phosphate retention and ac-
celerated ageing. As Klotho declines in CKD, it causes FGF-
23 resistance and induces FGF-23 and parathyroid hormone 
increases, and hypovitaminosis D. Klotho downregulation 
appears to be an early biomarker for kidney dysfunction and 
mineral dysregulation, may play a pathogenetic role in the 
progression of CKD, and it may also be responsible for vas-
cular calcification, which is one of the principal complications 
of CKD. The anti-calcification effect of Klotho may possibly 
be related to a phosphaturic action, the preservation of glo-
merular filtration rate (GFR), and a direct effect on soft tissues 
including the vascular smooth muscle. Thus, in clinical practice, 
Klotho can serve as an early and sensitive biomarker of CKD. 
Maintaining normal phosphate levels with use of phosphate 
binders in patients with CKD with declining Klotho expression 
is expected to ameliorate mineral and vascular derangements. 
Furthermore, Klotho replacement therapy or manipulation of 
up-regulation of endogenous Klotho may slow progression of 
CKD and also prevent and/or reverse its complications.7
Fibroblast growth factor 23 (FGF-23) is a recently dis-
covered secretory hormone, mainly produced by osteocytes, 
with main functions the inhibition of renal tubular phosphate 
reabsorption and the suppression of circulating vitamin D 
levels by decreasing synthesis and enhancing catabolism of 
vitamin D.9-11 FGF-23 participates in the bone/kidney axis that 
protects the organism from excess vitamin D and coordinates 
renal phosphate handling with bone mineralization/turnover. 
Abnormalities of FGF-23 production underlie many inherited 
and acquired disorders of phosphate homeostasis. Recent 
studies have shown that the function of FGF-23 is dependent 
on interaction with Klotho, as an obligate co-receptor, which 
binds FGF-23 and then activates FGF receptors.10 These 
proteins appear responsible for maintaining mineral-ion 
homeostasis, but also regulate cell survival, proliferation and 
vitamin D metabolism. Hereditary disorders that exhibit high 
serum FGF-23 levels are associated with phosphate wasting 
and impaired bone mineralization, whereas defects in either 
FGF-23 or Klotho are associated with phosphate retention 
and a premature-aging syndrome.3 The aging-like pheno-
types in Klotho-deficient or FGF-23-deficient mice can be 
managed by targeting and treating hyperphosphatemia with 
dietary or genetic manipulation, suggesting a novel concept 
that phosphate retention accelerates aging, as seen in CKD. 
Interestingly, a recent study indicated that elevated FGF-23 
levels were independently of klotho associated with left ven-
tricular hypertrophy (LVH) in a large, racially diverse CKD 
cohort.12 In addition to FGF-23, there are other endocrine 
FGFs that have been recognized as hormones that regulate a 
variety of metabolic processes. FGF-19 is secreted from the 
intestine during food intake and acts on liver to suppress bile 
acid synthesis. FGF-21 is secreted from the liver during fasting 
and acts on adipose tissue to promote lipolysis and responses 
to fasting. One critical feature of endocrine FGFs is that they 
require the Klotho gene family of transmembrane proteins 
as coreceptors to bind their related FGF receptors and exert 
their biological actions. 
Klotho is an antiageing protein that confers resistance to 
oxidative stress and several pathological conditions predis-
posing to cardiovascular-renal damage.5 Klotho is essential 
in calcium-phosphate metabolism and the maintenance of 
vascular integrity; it offers cardiorenal protection. Reduced 
levels of soluble Klotho are detected in the early stages of 
cardiovascular-renal disease; thus, Klotho might be consid-
ered as a useful biomarker that predicts atherosclerosis and 
vascular calcification. 
In a cohort of 804 adults of >65 years of the InCHIANTI 
study, a longitudinal population-based study of aging in Tus-
cany, Italy, plasma Klotho was an independent predictor of 
all cause mortality, with participants in the lowest tertile of 
plasma klotho (<575 pg/mL) having an increased risk of death 
compared with participants in the highest tertile of plasma 
klotho (>763 pg/mL; hazards ratio 1.78).13 The same authors 
reported similar findings in a larger cohort of 1023 individuals, 
aged 24-102 years, whereby higher plasma klotho concentra-
tions were independently associated with a lower likelihood 
of having cardiovascular disease.14 
In a recent study,15 thoracic aorta specimens from 44 pa-
tients who underwent elective cardiac surgery, and thrombus 
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material from 2 patients with acute coronary syndrome, were 
tested for FGF-23-Klotho system expression. It was found 
that human vascular tissue expresses members of the FGF23-
Klotho system, indicating that it can be a direct target organ 
for FGF-23. In addition, Klotho expression was detected in 
occlusive coronary thrombi. These findings suggest a putative 
role of FGF23-Klotho axis in human vascular pathophysiol-
ogy and cardiovascular disease. Another most recent study 
reported endogenous Klotho expression in human arteries, in 
vivo, and in human aortic smooth muscle cells, in vitro.16 The 
authors maintained that vascular Klotho deficiency in CKD, 
promoted by chronic metabolic stress factors found in CKD, 
may be a possible explanation for accelerated vascular aging 
with calcification observed in these patients. They also showed 
that high levels of FGF-23 in CKD cannot be vasculoprotective 
because Klotho/FGF-receptor deficiency mediates resistance 
and that vitamin D receptor activator therapy mediates vas-
cular protection by enhancing vascular Klotho expression and 
rendering vascular cells FGF-23 responsive. 
The potential use of FGF-23 – Klotho as an antiageing 
therapy is tempting; however, there is also lurking risk.10 Al-
though increased serum levels of active vitamin D are clearly 
responsible for several ageing-like phenotypes, including tis-
sue atrophy, moderate production of active vitamin D is still 
essential for normal bone mineralization. Also, vitamin D 
deficiency has been linked to increased risk in development 
of various forms of cancer or other diseases such as multiple 
sclerosis, diabetes mellitus, rheumatoid arthritis, osteoarthritis, 
hypertension, and stroke. Therefore, it is clear that a balance 
of moderate levels of systemic active vitamin D is essential for 
maintaining overall health and longevity. Nevertheless, Klotho 
pathways remain as potential targets for anti-ageing interven-
tions and reno-cardiovascular regulation and homeostasis.5,17 
Prevention of Klotho decline and supplementation of Klotho 
can be a novel therapeutic strategy for many age-related 
diseases.18,19 In a recent animal study, it was demonstrated 
that the administration of a vitamin D analogue and/or an 
angiotensin receptor blocker (olmesartan) improved chronic 
renal failure and up-regulated the klotho gene in the kidney.20 
In particular, the combination therapy of the 2 drugs provided 
the most effective renal protection. 
Although the seminal discovery of Klotho, the anti-ageing 
gene, may not have still increased our longevity, however, it 
has shed new light into our understanding of the role of the 
Klotho protein and mineral homeostasis in the pathogenesis 
of reno-cardio-vascular disease (Fig. 1). Our task still remains 
to unravel more secrets of function and potential therapeutic 
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Figure 1. Putative role of Klotho involvement in reno-cardio-vascular disease. CKD = chronic 
kidney disease; DM = diabetes mellitus; FGF = fibroblast growth factor; HTN = hypertension; 
LVH = left ventricular hypertrophy; NO = nitric oxide; PTH = parathyroid hormone; ROS = 
reactive oxygen species; vitD = vitamin D  
 
FiguRE 1. Putative role of Klotho involvement in reno-cardio-vascular disease. CKD = chronic kidney disease; DM = diabetes 
mellitus; FGF = fibroblast growth factor; HTN = hypertension; LVH = left ventricular hypertrophy; NO = nitric oxide; PTH = 
parathyroid hormone; ROS = reactive oxygen species; vitD = vitamin D.
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